Skip to content
TrialScanner

NCT04969861

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Phase 2/Phase 3TerminatedNKTRLeadMRKCollaborator

Registry record

Lead sponsor
Nektar Therapeutics
Conditions
Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer
Primary completion
Apr 22, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04969861 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04969861: BEMPEG With Pembrolizumab vs... | TrialScanner